Table 2.

Univariable analysis of patient characteristics related to fatal outcome of COVID-19. Risk (expressed in odds ratio) of a fatal outcome of COVID-19 for the different patients’ characteristics (n = 830).

	All patients (n = 830)
	Odds ratio (95% CI)	p-value
Sex (male)	1.93 (1.41–2.64)	<0.001
Age
<65 years	–	–
≥65 years < 75 years	4.83 (3.04–7.67)	<0.001
≥75 years	7.47 (4.75–11.74)	<0.001
Smoking	1.47 (1.08–1.99)	0.014
Comorbidities
Cardiovascular disease	2.38 (1.73–3.27)	<0.001
BMIa ≥ 30	0.70 (0.47–1.05)	0.081
COPDb	1.94 (1.23–3.07)	0.004
Diabetes mellitus	1.55 (1.07–2.26)	0.020
Autoimmune disease	1.21 (0.65–2.23)	0.546
Prior/other malignancy	2.78 (1.94–3.98)	<0.001
Use of steroids at COVID-19 diagnosis	1.75 (1.24–2.48)	0.002
As part of cancer treatmentc	0.96 (0.44–2.06)	0.910
Use >1 weekc	1.27 (0.60–2.71)	0.536
Cancer type
Other	–	–
Haematological malignancy	2.01 (1.40–2.89)	<0.001
Lung cancer	1.99 (1.28–3.11)	0.002
Last cancer treatment
Surgery	0.64 (0.36–1.11)	0.107
Radiotherapy	0.75 (0.48–1.17)	0.203
Thoracic radiotherapy	1.24 (0.72–2.13)	0.437
Chemotherapy	0.98 (0.72–1.33)	0.882
Immunotherapy	0.89 (0.59–1.34)	0.563
Targeted therapy	0.74 (0.48–1.15)	0.180
Hormonal therapy	1.02 (0.64–1.64)	0.923
Disease stage for solid tumours
Metastatic	0.95 (0.69–1.31)	0.768
Intention most recent cancer treatment given
Non-curative	1.27 (0.91–1.76)	0.154

COVID-19, coronavirus disease 2019.

^aBMI, body mass index.

^bCOPD, chronic obstructive pulmonary disease.

^cWithin group of patients with steroids- -